Unknown

Dataset Information

0

Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.


ABSTRACT: Herein, we report the structure-activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) positive allosteric modulators (PAMs). On the basis of its robust in vitro potency and in vivo efficacy in multiple preclinical models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, 17a (VU0409551/JNJ-46778212) was selected as a candidate for further development.

SUBMITTER: Conde-Ceide S 

PROVIDER: S-EPMC4492464 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


Herein, we report the structure-activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) positive allosteric modulators (PAMs). On the basis of its robust in vitro potency and in vivo efficacy in multiple preclinical models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, 17a (VU0  ...[more]

Similar Datasets

| S-EPMC4908650 | biostudies-literature
| S-EPMC6421540 | biostudies-literature
| S-EPMC5809351 | biostudies-literature
| S-EPMC4443790 | biostudies-literature
| S-EPMC3608436 | biostudies-literature
| S-EPMC5388536 | biostudies-literature
| S-EPMC4789665 | biostudies-literature
| S-EPMC5481018 | biostudies-literature
| S-EPMC6047034 | biostudies-literature
2022-01-03 | GSE182592 | GEO